HYPERPHOSPHATEMIA
Clinical trials for HYPERPHOSPHATEMIA explained in plain language.
Never miss a new study
Get alerted when new HYPERPHOSPHATEMIA trials appear
Sign up with your email to follow new studies for HYPERPHOSPHATEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to tame dangerous mineral in kidney patients
Disease control CompletedThis study tested a new drug called AP301 to see if it works as well as or better than a standard medication (sevelamer) at controlling high phosphorus levels in the blood of people on long-term dialysis. It involved 474 Chinese adults with chronic kidney disease who were receivi…
Matched conditions: HYPERPHOSPHATEMIA
Phase: PHASE3 • Sponsor: Alebund Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Year-long safety check for kidney disease phosphorus drug
Disease control CompletedThis study tested the long-term safety of MCI-196, a medication that helps control high phosphorus levels in people with advanced kidney disease who are on dialysis. The research followed 632 patients for up to one year to monitor how well they tolerated the medication and whethe…
Matched conditions: HYPERPHOSPHATEMIA
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug aims to tame dual threat for dialysis patients
Disease control CompletedThis large, completed Phase 3 trial tested whether the drug MCI-196 could help control two common problems in people with kidney failure on dialysis: high phosphorus and high 'bad' cholesterol. The study involved 642 stable dialysis patients who were randomly assigned to receive …
Matched conditions: HYPERPHOSPHATEMIA
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope for dialysis patients: drug fights dangerous mineral buildup
Disease control CompletedThis study tested whether the drug MCI-196 could safely control high phosphorus levels in people with kidney failure on dialysis. Researchers compared the drug against a placebo in 336 patients over 16 weeks. The goal was to see if the drug could effectively manage this common an…
Matched conditions: HYPERPHOSPHATEMIA
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for dialysis patients struggling with dangerous mineral levels
Disease control CompletedThis study tested whether a drug called MCI-196 could safely and effectively control high phosphorus levels in the blood of adults with kidney failure who are on dialysis. After a 12-week period where all participants received the drug, some were randomly switched to a placebo (d…
Matched conditions: HYPERPHOSPHATEMIA
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug tested for Long-Term safety in dialysis patients
Disease control CompletedThis study tested the long-term safety and effectiveness of a drug called MCI-196 for people on dialysis who have high phosphate levels in their blood. It involved 116 adult patients on stable dialysis treatment. The main goal was to see how safe the drug was over a year, while a…
Matched conditions: HYPERPHOSPHATEMIA
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
Scientists check timing of kidney pills
Knowledge-focused CompletedThis study aimed to see if taking a phosphate-lowering drug (colestilan) changes how the body absorbs a common blood pressure medication (candesartan). It involved 18 healthy male volunteers to measure drug levels in the blood under different timing schedules. The goal was to gat…
Matched conditions: HYPERPHOSPHATEMIA
Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC